These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2443 related items for PubMed ID: 22801398

  • 1. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F, Larsen TB, Rasmussen LH, Lip GY.
    Thromb Haemost; 2014 May 05; 111(5):981-8. PubMed ID: 24577485
    [Abstract] [Full Text] [Related]

  • 7. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.
    Circ Cardiovasc Qual Outcomes; 2012 Jul 01; 5(4):480-6. PubMed ID: 22787066
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.
    Clin Ther; 2014 Feb 01; 36(2):192-210.e20. PubMed ID: 24508420
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP, Halperin JL.
    Hosp Pract (1995); 2013 Feb 01; 41(1):37-48. PubMed ID: 23466966
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
    Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.
    Am J Cardiol; 2012 Aug 01; 110(3):453-60. PubMed ID: 22537354
    [Abstract] [Full Text] [Related]

  • 16. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ.
    Postgrad Med; 2012 Nov 01; 124(6):7-16. PubMed ID: 23322134
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA.
    Value Health; 2013 Jun 01; 16(4):498-506. PubMed ID: 23796283
    [Abstract] [Full Text] [Related]

  • 18. {blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
    Drug Ther Bull; 2014 Jan 01; 52(1):6-9. PubMed ID: 24401533
    [Abstract] [Full Text] [Related]

  • 19. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Yates SW.
    Hosp Pract (1995); 2011 Oct 01; 39(4):7-16. PubMed ID: 22056819
    [Abstract] [Full Text] [Related]

  • 20. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
    Aguilar MI, Kuo RS, Freeman WD.
    Neurol Clin; 2013 Aug 01; 31(3):659-75. PubMed ID: 23896498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 123.